In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), expansion cohorts are now open and enrolling patients with these tumor types; based on an additional response in a patient with Hodgkin lymphoma, a further expansion cohort of patients with Hodgkin lymphoma will begin shortly. The IND application for CTX-10726 (PD-1 x VEGF-A bispecific antibody) received FDA clearance...

‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights:CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed $91.2 million...

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX:STCK; TSX:STCK.WT.A; TSX:STCK.WT.B) today announced its financial results for the year ended December 31, 2025. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. FINANCIAL SUMMARYBook Value per Share (BVpS): $15.35, compared to $12.29 as at December 31, 2024 (+24.9% increase) Total Book Value: $202 millionThe increase in Book Value during the year reflects strong performance across core portfolio holdings and disciplined capital deployment across late-stage private market opportunities. PORTFOLIO COMPANY HIGHLIGHTS SpaceXCompleted a tender offer transaction valuing the company at US$800 billion, reflecting continued investor demand and confidence in its long-term growth trajectory Subsequent...

Fourth Quarter Highlights and Recent DevelopmentsFourth quarter revenue of $32.9 million, up 26% q/q, 148.9% y/y, in line with target guidance Gross margin improvement of approximately 1,500 basis points q/q and 4,900 points y/y Awarded 1GW supply agreement with leading developer for 1P and 2P trackers in U.S. Secured 840MW supply agreement with Lubanzi for 1P and 2P trackers in South AfricaAUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, today announced financial results for the fourth quarter that ended December 31, 2025. “I’m pleased to share that our fourth quarter results came in at the high-end of our target ranges and we continued to position the company for long-term success,” said Yann Brandt, President and Chief Executive Officer of FTC Solar....

Virtuix: Pioneering Movement in AI-Generated WorldsNet Sales up 41% to $3.0 Million in Nine Months Ended December 31, 2025 Gross Margin Increased by 46% and Operating Expenses Decreased by 45% Strategic Collaboration with Meta and Global Expansion Accelerate Omni One Adoption and Scale AI-Enabled Defense Training and Enterprise Applications Advance Multi-Use Growth Strategy Virtuix Rang the Nasdaq Closing Bell on March 4, 2026 Management to Host Conference Call Today at 8:30 a.m. Eastern Time AUSTIN, Texas, March 05, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX) (the “Company”), a leading developer of full-body virtual reality systems, today reported financial and operational results for the three and nine months ended December 31, 2025. Figures presented herein are approximate and have been minimally...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 DECLARATION trial on track with full enrollment achieved DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and breastfeeding women in the DECLARATION trial DECLARATION trial blinded, pooled early COVID event...

Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line Guidance Comparable Sales Increased 8% in the Fourth Quarter and 5% for the Full Year Fourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded Expectations Initiates First Quarter and Fiscal 2026 GuidanceREYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super, VS&Co Chief Executive Officer, said, “We delivered an exceptional fourth quarter and a standout year, exceeding top- and bottom-line guidance with broad based outperformance across brands, channels and geographies. We drove meaningful acceleration in the second half of the year, with fourth quarter...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates. “Throughout 2025, we translated strategy into disciplined execution and meaningfully advanced our pipeline,” said Aoife Brennan, M.B.,...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generationDURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026. “Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened...

ATHENS, Greece, March 05, 2026 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (the “Company”, “CCEC”, “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today released its financial results for the fourth quarter ended December 31, 2025. Key Quarterly HighlightsOrdered three latest-technology LNG carriers with deliveries in 2028 and 2029 Concluded the sale of a 13,696 TEU container vessel, the M/V Buenaventura Express Took delivery of our first LCO2/multi-gas carrier, the Active Announced dividend of $0.15 per share for the fourth quarter of 2025Key Financial Highlights (continuing operations)  Three-month period ended December 31,  2025 2024 Increase/(Decrease)Revenues $98.3 million $97.6 million 0.7%Expenses $44.8 million $44.5 million 0.7%Interest expense and finance cost $23.9...